Tissue Phenomics Blog

5B_Her2-classified.jpg

Posts by Topic

see all

Topics:  Immunotherapy, personalized medicine, cancer diagnostics, precision medicine, cancer vaccines

Promising results with personalized cancer vaccines highlight the need for novel diagnostics to personalize cancer treatments

Aug 9, 2017 7:00:00 AM

Personalized medicine aims at bringing the right drug to the right patient at the right time. Getting many things right at the same time is challenging. There are many potential treatments for cancer patients and many of these can be combined with each other resulting in a lot of potential combination treatments. This growing number of treatment options makes it increasingly difficult to determine the right one for an individual patient. Biomarkers that help to predict response to a treatment are highly needed to guide treatment selection to maximize efficiency for both patients and payers.

Read More

Topics:  predictive test, image analysis, clinical trials, Immunotherapy, oncology, tumor microenvironment

Evaluation of the Tumor Microenvironment Using Image Analysis for Clinical Trials

May 8, 2017 7:30:00 AM

Advances in immunotherapy have dramatically changed the landscape for cancer researchers. With significant improvements in overall survival and recurrent free survival in some of the deadliest cancers, lives have been extended by years for some patients while other patients have not experienced benefit from immunotherapy treatment. For some cancer indications, such as non-small cell lung cancer, the FDA approved companion diagnostic test for PD-L1 by immunohistochemistry has predictive value on patient response. However, the test is not a perfect indicator of response as some PD-L1 negative patients will respond to therapy and, conversely, some PD-L1 positive patients will not. At the same time, the number of clinical trials examining immunotherapy and combination therapies with immunotherapy as a backbone has exceeded 1000 in 2017. The possibility of combination therapy brings many questions to light for the researcher and ultimately the physician on which therapy to choose, for how long, in what order and what potential combination. With these questions, comes the increasing need for predictive tests that can lead the physician to the right therapy at the right time.

Read More

Topics:  Immunotherapy, immunoscore, immuno-oncology, cancer therapy

The Top 3 Major Contributions to Immuno-oncology in 2016

Feb 6, 2017 8:29:57 AM

Immuno-oncology was a super-hot topic in 2016. Several thousand publications contributed to the scientific progress, so choosing the top 3 is a challenging undertaking. But there are a few common themes seen in many highly ranked publications: the use of the latest hard- and software to gain an improved mechanistic understanding, why immuno-oncology actually works, and guidance on how to both design and predict individual patient success of novel therapies.

Read More

Topics:  image analysis, Immunotherapy, immuno-oncology, tissue phenomics, real world evidence

Three reasons image analysis should be incorporated into your immunotherapy real-world evidence development strategy

Jan 9, 2017 5:00:00 AM

Clinical trials are extremely important to assess the safety and effectiveness of a new therapy or of a currently-available therapy in a new indication. However, there are a few drawbacks to clinical trials, such as:

Read More

Topics:  image analysis, clinical trials, drug development, Immunotherapy, immuno-oncology, predictive biomarkers, cancer treatment

How Image Analysis Can Improve the Results of Drug Development and Clinical Trials

Dec 12, 2016 4:00:00 AM

In recent years there have been several potentially life-saving medications approved for cancer treatment, including targeted molecular entities and biologics such as Opdivo (nivolumab) and Keytruda (pembrolizumab). Oncology drugs remain a pharmaceutical priority and investments into cancer account for 30% of all pre-clinical and phase 1 clinical development expenditures. There is an impressive list of close to 800 drugs and vaccines currently in the industry-wide development pipeline, many with promising results in early-stage clinical trials. However by historical measures only 10% or fewer of these drugs will ever make it through FDA approval and become part of routine patient care.

Read More